TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge
April 22, 2015 3:50 PM EDTBaird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.
The analyst said the challenge does not come as a surprise and they predicted this in February after... More
Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - Bloomberg
April 22, 2015 11:13 AM EDTKyle Bass files challenge to Biogen (NASDAQ: BIIB) patent on Tecfidera - Bloomberg
... MoreBiogen Idec (BIIB) Announces Significant Data from TECFIDERA in MS
April 20, 2015 7:31 AM EDTBiogen Idec (NASDAQ: BIIB) announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis (MS). Data show TECFIDERA significantly reduced relapses and disability progression in newly-diagnosed relapsing-remitting MS (RRMS) patients who had highly active disease. Additional data indicate TECFIDERA showed strong and sustained efficacy over five years in RRMS patients who... More
